US FDA Approves AbbVie's Tavapadon for Parkinson's Disease
核心洞察
The US Food and Drug Administration (搜索) has approved AbbVie's tavapadon, brand name Juvmo (搜索), for Parkinson's disease (搜索) in adults, per the regulator's website.
Juvmo (搜索) is dosed as a once-a-day pill for a long-term brain condition that progressively damages movement control.
AbbVie obtained tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.
The US Food and Drug Administration (搜索) has approved AbbVie's tavapadon for Parkinson's disease (搜索) in adults, according to the regulator's website. The drug carries the brand name Juvmo (搜索) and is given as a once-a-day pill.
Parkinson's is a long-term brain condition that gradually damages movement control, often causing tremors, stiffness and balance issues.
AbbVie gained access to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.
Source: Yahoo News Singapore